NASDAQ:NBIX - Neurocrine Biosciences Stock Price, News, & Analysis

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its quarterly earnings results on Tuesday, July, 31st. The company reported ($0.07) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.18) by $0.11. The firm had revenue of $96.90 million for the quarter, compared to the consensus estimate of $84.11 million. Neurocrine Biosciences had a negative net margin of 16.07% and a negative return on equity of 14.22%. The business's revenue was up 1428.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.68) earnings per share. View Neurocrine Biosciences' Earnings History.

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, November, 7th 2018. View Earnings Estimates for Neurocrine Biosciences.

15 brokers have issued 1 year price targets for Neurocrine Biosciences' shares. Their forecasts range from $79.00 to $162.00. On average, they anticipate Neurocrine Biosciences' stock price to reach $117.20 in the next year. This suggests a possible upside of 2.3% from the stock's current price. View Analyst Price Targets for Neurocrine Biosciences.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurocrine Biosciences.

Some companies that are related to Neurocrine Biosciences include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), bluebird bio (BLUE), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Aerie Pharmaceuticals (AERI), argenx (ARGX), Halozyme Therapeutics (HALO), Crispr Therapeutics (CRSP), Spark Therapeutics (ONCE), Acceleron Pharma (XLRN) and Regenxbio (RGNX).

News articles about NBIX stock have trended positive recently, according to Accern Sentiment. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Neurocrine Biosciences earned a media and rumor sentiment score of 0.32 on Accern's scale. They also gave news articles about the company an impact score of 42.66 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Neurocrine Biosciences.

Neurocrine Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (14.87%), Janus Henderson Group PLC (8.20%), BB Biotech AG (3.67%), Artisan Partners Limited Partnership (2.08%), First Trust Advisors LP (1.09%) and OppenheimerFunds Inc. (0.94%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Stephen A Sherwin, Timothy P Coughlin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.

NBIX stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Frontier Capital Management Co. LLC, Millennium Management LLC, Artisan Partners Limited Partnership, BB Biotech AG, Federated Investors Inc. PA, Janus Henderson Group PLC and Massachusetts Financial Services Co. MA. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Stephen A Sherwin and William H Rastetter. View Insider Buying and Selling for Neurocrine Biosciences.

NBIX stock was bought by a variety of institutional investors in the last quarter, including Braun Stacey Associates Inc., Boston Advisors LLC, American Century Companies Inc., PointState Capital LP, Macquarie Group Ltd., Orbimed Advisors LLC, FMR LLC and Columbus Circle Investors. View Insider Buying and Selling for Neurocrine Biosciences.

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NBIX stock can currently be purchased for approximately $114.62.

Neurocrine Biosciences has a market capitalization of $10.72 billion and generates $161.63 million in revenue each year. The company earns $-142,540,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Neurocrine Biosciences employs 400 workers across the globe.

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]